Related Experiment Video
Updated: Jun 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
The clinical pharmacology of eplerenone
James A Muldowney1, John A Schoenhard, Cassandra D Benge
1Vanderbilt University Medical Center, Division of Cardiovascular Medicine, Department of Internal Medicine, 383 Preston Research Building, Nashville, Tennessee 37232-6300, USA. james.muldowney@vanderbilt.edu
Abstract:
Eplerenone is an aldosterone receptor antagonist indicated for the treatment of hypertension and congestive heart failure. Eplerenone contains an epoxy group, which offers greater mineralocorticoid receptor specificity. It is an effective antihypertensive that has been shown to reduce morbidity and mortality in individuals with left ventricular dysfunction post myocardial infarction. Studies are continuing to determine whether the benefit of mineralocorticoid receptor blockade in advanced congestive heart failure is also observed when eplerenone treatment is initiated in earlier stages of the disease. The most common side effect is hyperkalemia necessitating close monitoring in individuals with diabetes and proteinuria, heart failure or in those who are taking moderate CYP450 3A4 inhibitors. It is category B in pregnancy.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure II: Pathophysiology
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics